Pradofloxacin: A novel veterinary fluoroquinolone for treatment of bacterial infections in cats

被引：21
|
作者：
Sykes, Jane E. [1 ,3 ,4 ]
Blondeau, Joseph M. [2 ,5 ]
机构：
[1] Univ Calif Davis, Dept Med & Epidemiol, Davis, CA 95616 USA
[2] Saskatoon Hlth Reg, Royal Univ Hosp, Dept Pathol & Lab Med, Saskatoon, SK S7N 0W8, Canada
[3] Saskatoon Hlth Reg, Royal Univ Hosp, Dept Microbiol & Immunol, Saskatoon, SK S7N 0W8, Canada
[4] Saskatoon Hlth Reg, Royal Univ Hosp, Dept Ophthalmol, Saskatoon, SK S7N 0W8, Canada
[5] Univ Saskatchewan, Saskatoon, SK S7N 0W8, Canada
来源：
VETERINARY JOURNAL | 2014年 / 201卷 / 02期
关键词：
Antimicrobial; Minimum inhibitory concentration; Pharmacodynamics; Pharmacokinetics; Resistance; MUTANT PREVENTION CONCENTRATION; STREPTOCOCCUS-PNEUMONIAE; ESCHERICHIA-COLI; RETINAL DEGENERATION; SUSCEPTIBILITY; ENROFLOXACIN; RESISTANCE; SELECTION; AZITHROMYCIN; DOGS;
D O I：
10.1016/j.tvjl.2014.06.008
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
Pradofloxacin is a novel third-generation oral veterinary fluoroquinolone with activity against Gram-positive aerobic bacteria and anaerobes (lower minimum inhibitory concentrations in vitro). It also has activity against other bacterial species, including Bartonella henselae, Pasteurella multocida, Bordetella bronchiseptica, extra-intestinal Escherichia coli, and some mycobacterial species. This review focuses on the current knowledge of the mechanism of action, adverse effects, clinical applications, and pharmacokinetic/pharmacodynamic properties of pradofloxacin in cats. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：207 / 214
页数：8
相关论文
共 50 条
  • [1] Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography
    Andre Messias
    Florian Gekeler
    Alfred Wegener
    Klaus Dietz
    Konrad Kohler
    Eberhart Zrenner
    Documenta Ophthalmologica, 2008, 116 : 177 - 191
  • [2] Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography
    Messias, Andre
    Gekeler, Florian
    Wegener, Alfred
    Dietz, Klaus
    Kohler, Konrad
    Zrenner, Eberhart
    DOCUMENTA OPHTHALMOLOGICA, 2008, 116 (03) : 177 - 191
  • [3] Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis
    Bertino, Joseph S.
    Zhang, Jin-Zhong
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (15) : 2545 - 2554
  • [4] Besifloxacin: A Topical Fluoroquinolone for the Treatment of Bacterial Conjunctivitis
    Chang, Mei H.
    Fung, Horatio B.
    CLINICAL THERAPEUTICS, 2010, 32 (03) : 454 - 471
  • [5] The use of fluoroquinolones in bacterial urinary tract infections in cats
    Kramer, S.
    Kietzmann, M.
    Pankow, W. -R.
    TIERAERZTLICHE PRAXIS AUSGABE KLEINTIERE HEIMTIERE, 2012, 40 (02): : 113 - 121
  • [6] Questions associated with the development of novel drugs intended for the treatment of bacterial infections in veterinary species
    Martinez, Marilyn N.
    Watts, Jeffrey L.
    Gilbert, Jeffrey M.
    VETERINARY JOURNAL, 2019, 248 : 79 - 85
  • [7] Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
    Jones, Travis M.
    Johnson, Steven W.
    DiMondi, V. Paul
    Wilson, Dustin T.
    INFECTION AND DRUG RESISTANCE, 2016, 9 : 119 - 128
  • [8] A Phase II Study of Antofloxacin Hydrochloride, a Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections
    Wang, Jin
    Xiao, Yonghong
    Huang, Wenxiang
    Xu, Nan
    Bai, Chunxue
    Xiu, Qingyu
    Mei, Changlin
    Zheng, Qingshan
    CHEMOTHERAPY, 2010, 56 (05) : 378 - 385
  • [9] Novel Mechanistic Insights into Bacterial Fluoroquinolone Resistance
    Du, Gao-Fei
    Zheng, Yun-Dan
    Chen, Jing
    He, Qing-Yu
    Sun, Xuesong
    JOURNAL OF PROTEOME RESEARCH, 2019, 18 (11) : 3955 - 3966
  • [10] High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli
    Rattanaumpawan, Pinyo
    Nachamkin, Irving
    Bilker, Warren B.
    Roy, Jason A.
    Metlay, Joshua P.
    Zaoutis, Theoklis E.
    Lautenbach, Ebbing
    ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2017, 16
12345